ABSTRACT

Every woman may experience an irregular menstrual cycle once in a while. The late menstruation or missed period may be the irregularity. But, when this irregularity reaches a long interval, the condition is called as oligomenorrhea. Myo-inositol is one of the molecules which plays a key role in the mechanism of ovulation. The goal of the study is to assess the adherence and outcome of myo-Inositol in the patients who are reported for the complaints of oligomenorrhea in RMMCH and to establish that this molecule can be used as safer in treating patients with oligomenorrhea. It is a Prospective observational study. The data were collected based on the questions involved in the data collection form with consent to the patient willingness. Patient’s medication adherence was checked using Morisky medication adherence scale. Patient counselling was provided in terms of oral method.The report showed that there is a significant improvement in the patient’s medication adherence after the patient counseling as the calculated ‘t’ value 7.298 is greater than the critical or two sided table ‘t’ value, 2.0096. The study also shown a strong evidence (t = 21.025, p < 0.05) and these data support the beneficial outcome of myo- inositol in women with oligomenorrhea, as the calculated ‘t’ value 21.025 is greater than the critical or two-sided table ‘t’ value 2.0154.The study concludes that patient counselling improved the medication adherence significantly among the study population. This study also suggests that there is a positive role for myo-inositol in regularising the menstrual cycle in patients with oligomennorrhea. No Adverse Drug Reactions were reported during the study. This may be due to the small sample size. Keywords: Myo-inositol, oligomennorrhea, Morisky medication
Publication date: 01/05/21

https://ijbpas.com/pdf/2021/May/MS_IJBPAS_2021_5473.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.5.5473